Other Cardiovascular Agents

This topic is a reference category for cardiovascular drugs that do not belong to the principal antihypertensive, antiarrhythmic, lipid-modifying, or nitrate classes. It includes agents with distinctive single-target mechanisms — such as ivabradine, which selectively slows the sinoatrial pacemaker current, and ranolazine, which inhibits the late sodium current to improve myocardial energetics in angina.

Definition

Other cardiovascular agents are pharmacological agents acting on the cardiovascular system whose mechanisms place them outside the principal antihypertensive, antiarrhythmic, lipid-modifying, and nitrate classes — for example selective sinoatrial If-current inhibitors and late-sodium-current inhibitors.

Scope

The entry orients the reader to the heterogeneous 'other' cardiovascular agents and their characteristic mechanisms and uses, with brief evidence context. It is a pharmacological reference and does not provide dosing or individualized therapeutic advice.

Core questions

• Which cardiovascular drugs fall outside the major established classes?
• What single-target mechanisms define agents such as ivabradine and ranolazine?
• What clinical roles do these agents fill that the major classes do not?
• How is heart rate itself a therapeutic target in heart failure?

Key concepts

• Funny current (If) inhibition by ivabradine
• Selective sinoatrial node rate reduction
• Late sodium current inhibition by ranolazine
• Myocardial energetics and ischaemia
• Heart rate as a risk factor
• Residual category in drug classification

Key theories

Heart rate as a modifiable therapeutic target

In chronic heart failure with reduced ejection fraction and sinus rhythm, elevated resting heart rate is associated with worse outcomes, and selectively lowering it with an If-current inhibitor without other haemodynamic effects can improve outcomes, supporting heart rate as a target distinct from blood pressure or rhythm.

Mechanisms

The agents in this category act through narrowly defined targets. Ivabradine selectively inhibits the hyperpolarization-activated 'funny' current (If) in sinoatrial node cells, slowing diastolic depolarization and lowering heart rate without depressing contractility or blood pressure. Ranolazine inhibits the late inward sodium current in cardiomyocytes, reducing sodium- and calcium-mediated overload during ischaemia and improving myocardial relaxation and oxygen efficiency, which underlies its anti-anginal effect. These mechanisms sit alongside the broader nitric-oxide / cyclic-GMP and receptor-based pathways that define the rest of cardiovascular pharmacology, and the category remains a residual one that absorbs agents not captured by the main classes.

Clinical relevance

These agents fill specific niches — rate control in selected heart-failure patients and symptomatic relief in chronic stable angina — where the major classes are insufficient or contraindicated. This entry describes their mechanisms and trial context for educational reference and is not a basis for prescribing or for individual treatment decisions.

Epidemiology

Use of these agents is targeted rather than population-wide. Randomized evidence supports heart-rate reduction with ivabradine in selected patients with heart failure and reduced ejection fraction in sinus rhythm, and these agents are positioned in guidelines as second-line or adjunctive options rather than foundational therapy.

History

As cardiovascular pharmacology matured, agents emerged that did not fit the established classes but addressed unmet needs through novel single targets. Ivabradine, by isolating the sinoatrial funny current, provided a way to lower heart rate independent of beta-blockade, and trials linking heart rate to outcomes in heart failure validated the strategy. Ranolazine extended anti-anginal therapy to a metabolic mechanism. These additions are reflected in successive heart-failure and angina guidelines.

Debates

How broadly should heart-rate-lowering with ivabradine be applied?

Benefit is clearest in heart failure with reduced ejection fraction, sinus rhythm, and elevated heart rate despite background therapy; extending its use beyond that selected population, and its role relative to optimal beta-blockade, remains debated.

Key figures

• Michael Böhm
• Karl Swedberg
• Jeffrey Borer

Seminal works

• bohm-2010

Frequently asked questions

How does ivabradine lower heart rate differently from a beta-blocker?

Ivabradine selectively inhibits the sinoatrial 'funny' current (If) that sets the pacemaker rate, slowing the heart without the negative effects on contractility and blood pressure that accompany beta-blockade.

Why is this called a category of 'other' agents?

It is a residual reference grouping for cardiovascular drugs whose mechanisms place them outside the principal antihypertensive, antiarrhythmic, lipid-modifying, and nitrate classes.